Twist Bioscience Corporation·Healthcare

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) CFO Adam Laponis sold 2,597 shares of the company's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $49.89, for a total value of $129,564.33. Following the completion of the transaction, the chief financial officer directly owned

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) Director Melissa Starovasnik sold 1,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the

SG Americas Securities LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ: TWST) by 350.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 76,484 shares of the company's stock after acquiring an additional 59,500 shares during the quarter. SG Americas Securities LLC

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price

Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Analyst Ratings This is a summary of current

Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Healthcare
Medical - Diagnostics & Research
923
2018-10-31
2.21